Towards Healthcare Research & Consulting
Drug Repurposing Market
Updated Date: 27 July 2026   |   Report Code: 6424
[email protected] +1 804-441-9344
Download Sample Order Now

Drug Repurposing Market Trends and Forecast Analysis 2026 to 2035

According to Payal Rabde, who specializes in identifying new therapeutic used for existing approved or investigational drugs, reducing drug development time, cost, and clinical risks, and accelerating treatment development for rare, chronic and infectious diseases, with 4+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the drug repurposing market. The global drug repurposing market size was estimated at USD 636.95 million in 2025 and is predicted to increase from USD 730.96 million in 2026 to approximately USD 2506.64 million by 2035, expanding at a CAGR of 14.76% from 2026 to 2035. Her analysis highlights the increasing adoption of artificial intelligence (AI) and machine learning for drug discovery, computational biology and bioinformatics platforms, precision medicine and biomarket-driven therapies, cost-effective and faster drug development strategies, and growing collaborations among pharmaceutical companies, biotech firms, and research institutions. The research also examines the competitive strategies of key industry participants, Lonza, Excelra, Fios Genomics, Novartis AG, Paradigm Biopharmaceuticals Ltd, Sosei Group Corporation, and Teva Pharmaceutical Industries, shaping the future by advancing AI-driven target identification and drug repurposing platforms, expanding real-world evidence and multi-omics data integration, accelerating precision medicine and personlized treatment approaches, and enabling faster development of therapies for rare, infectious and chronic in the global drug repurposing market.

Last Updated : 27 July 2026 Category: Pharmaceuticals Insight Code: 6424 Format: PDF / PPT / Excel

Content

Chapter 1: Introduction

  • Market Definition & Taxonomy
  • Research Objectives
  • Market Scope & Assumptions
  • Study Timeline (Historical, Base Year, Forecast Period)
  • Key Stakeholders Covered

Chapter 2: Research Methodology

  • Research Framework Overview
  • Market Size Estimation Methodology
    • Bottom-Up Approach
    • Top-Down Approach
  • Forecasting Model
    • Dependent Variables
    • Independent Variables
    • Key Assumptions & Weightages
  • Primary Research Insights
  • Secondary Data Sources
  • Data Validation & Triangulation

Chapter 3: Executive Summary

  • Global & Regional Overview (Value, CAGR)
  • Epidemiology Snapshot
  • Segmental Overview
  • Competition Key Snippets
  • Strategic Takeaways

Chapter 4: Market Catalysts, Constraints & Growth Levers

  • Market Dynamics
  • Market Drivers/Catalysts
    • Driver 1
    • Driver 2
  • Market Restraints
    • Restraint 1
    • Restraint 2
  • Market Opportunities
    • Opportunity 1
    • Opportunity 2
  • Market Trends
    • Trend 1
    • Trend 2
  • Impact Assessment of Drivers, Restraints, Opportunities & Trends (High, Mid, & Low)

Chapter 5: Value Added Intelligence

  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers: Low/Moderate/High
    • Bargaining Power of Buyers: Low/Moderate/High
    • Threat of New Entrants: Low/Moderate/High
    • Threat of Substitute: Low/Moderate/High
    • Competitive Rivalry: Low/Moderate/High
  • PESTEL Analysis
  • Ecosystem Analysis
  • Mapping of Key Players
  • Value Chain Analysis
  • Margin Analysis Across Value Chain
  • Macro & Micro Factors Impacting Market
  • Market Potential Evaluation, By Region
  • Epidemiology & Patient Pool Analysis
    • Disease Incidence & Prevalence
    • Target Patient Pool
      • Diagnosed Population
      • Service-Seeking Population
    • Patient Flow & Utilization Analysis
      • Patient Footfall
      • Admission Rates
      • Procedure Volume
    • Healthcare Infrastructure Analysis
      • Number of Facilities
        • Hospitals
        • Clinics
        • Diagnostic Centers
        • ASCs
      • Bed Capacity
        • Total Beds
        • ICU Beds
      • Facility Distribution
    • Operational Metrics Analysis
      • Bed Occupancy Rate (%)
      • Average Length of Stay (ALOS)
    • Service Pricing & Revenue Model
      • Pricing Analysis
        • Cost per Procedure
        • Cost per Consultation
        • Cost per Diagnostic Test
      • Revenue Streams
        • Inpatient Services
        • Outpatient Services
        • Ancillary Services
      • Workforce & Staffing Analysis
        • Healthcare Workforce
          • Physicians
          • Nurses
          • Technicians
        • Staff-to-Patient Ratios
        • Skill Gap Analysis
        • Labor Cost Structure
      • Scenario Analysis (Base / Optimistic / Pessimistic)
      • Risk Assessment & Sensitivity Analysis
      • Opportunity Analysis, By Region
      • Regulatory Analysis
      • Sustainability & ESG Insights
      • Business Models
      • Investment & Funding Landscape
      • Key Conferences and Events

Chapter 7: Segmental & Regional Analysis

  • Global Drug Repurposing Market Analysis, By Type of Approach
    • Market Size, Forecast & CAGR, By Type of Approach, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Drug Repurposing Market Analysis, By Therapeutic Area
    • Market Size, Forecast & CAGR, By Type of Approach, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Drug Repurposing Market Analysis, By Drug Molecules
    • Market Size, Forecast & CAGR, By Type of Approach, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global Drug Repurposing Market Analysis, By Region
    • Market Size, Forecast & CAGR, By Type of Approach, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Drug Repurposing Market Analysis
  • North America Drug Repurposing Market Analysis, By Type of Approach, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Drug Repurposing Market Analysis, By Therapeutic Area, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Drug Repurposing Market Analysis, By Drug Molecules, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America Drug Repurposing Market Analysis, By Country, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
      • U. S. Drug Repurposing Market Analysis
    • U. S. Drug Repurposing Market Analysis, By Type of Approach, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U. S. Drug Repurposing Market Analysis, By Therapeutic Area, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U. S. Drug Repurposing Market Analysis, By Drug Molecules, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis

Similar Analysis will be given for each country and each region

  • Canada
  • Mexico
  • Rest of North America

Europe

  • Western Europe
  • Germany
  • Italy
  • France
  • Spain
  • UK
  • Netherlands
  • Switzerland
  • Nordic Countries
  • Rest of Western Europe
  • Eastern Europe
  • Austria
  • Russia & Belarus
  • Poland
  • Türkiye
  • Rest of Eastern Europe

Asia Pacific

  • China
  • Taiwan
  • India
  • Japan
  • Vietnam
  • Australia and New Zealand
  • ASEAN Countries
  • South Korea
  • Rest of APAC

South America

  • Brazil
  • Argentina
  • Rest of South America

Middle East and Africa (MEA)

  • GCC Countries
  • South Africa
  • Egypt
  • Rest of MEA

Chapter 6: Competitive Insights

  • Competitive Analysis
    • Company Evaluation Matrix
      • Major Players
      • Mid-Sized Companies
      • Emerging Players/Start-Ups
    • Global Market Share Analysis, By Region, 2025 (%)
    • Key Player Positioning
    • Competitive Benchmarking
      • By Type of Approach
      • By Therapeutic Area
      • By Drug Molecules
    • Strategies of Key Players
    • Insight From the Horse’s Mouth
  • Company Profiles
    • Excelra
      • Company Name
      • Company Headquarters
      • Management Overview
        • Key C-Suite Executives
          • CEO
          • MD
          • Others
        • Employee Count
        • Business Strategy
          • Key Investments Made
          • Future Plans
          • R&D & Innovation Capabilities
          • Recent Developments
            • New Product Launch
            • Merger & Acquisitions
            • Partnerships & Collaborations
            • Market Expansion
            • Others
          • Service Portfolio
          • Facility Network
            • Number of Facilities
            • Bed Capacity
            • Facility Distribution
            • Expansion Pipeline
          • Key Financials (2022-2025)
            • Revenue By Segment
            • Revenue By Service
            • Revenue By Geography
            • Financial Matrix (Gross Profit Margins, Net Margins, etc.)
          • Key Clients
            • Client Company Name
            • Key Contact Person
            • Contact Details
          • Regulatory & Certification Expertise
          • SWOT Analysis
    • Fios Genomics
    • Lantern Pharma, Inc.
    • Novartis AG
    • Paradigm Biopharmaceuticals Ltd
    • Predictive Oncology
    • Segue Therapeutics, LLC
    • Sosei Group Corporation
    • Teva Pharmaceutical Industries

FAQ's

Answer : The drug repurposing market holds a valuation of USD 730.96 million as of 2026, and will expand to USD 2506.64 million by 2035, achieving a CAGR of 14.76%.

Answer : North America is currently leading the drug repurposing market due to the presence of advanced research infrastructure and supportive regulatory guidelines.

Answer : The drug repurposing market includes four segments such as by type of approach, by therapeutic area, by drug molecules, and by region.
Any Questions

Meet the Team

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar